Press releases

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships …: you can find all the latest Ipsen Group press releases arranged by year.

Filter by date
30 / 05 / 2018 - Paris (France)
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 30 May 2018
Download ( pdf - 154 kB)
19 / 09 / 2017 - Paris (France)
Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

Download

 

16 / 08 / 2017 - Paris (France)
Exelixis submits U.S. supplemental new drug application for Cabometyx®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer
Download Press Release ( pdf - 210 kB)
10 / 07 / 2017 - Paris (France)
Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

 

– First phase 3 trial in a global clinical development program to explore the combination of these agents –

 

– Exelixis, Bristol-Myers Squibb and Ipsen to co-fund this trial –

Download ( pdf - 188 kB)
15 / 06 / 2017 - Paris (France)
Ipsen’s Partner Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Download ( pdf - 183 kB)
01 / 03 / 2017 - Paris (France)
Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.
Download ( pdf - 191 kB)
27 / 02 / 2017 - Paris (France)
Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.
Download ( pdf - 179 kB)
23 / 07 / 2016 - Paris
Ipsen annonce l’autorisation par la FDA de Dysport® (abobotulinumtoxinA) injection dans le traitement de la spasticité des membres inférieurs chez l’enfant âgé de 2 ans et plus
17 / 12 / 2015 - Paris (France)
Ipsen announces its corporate agenda for 2016
17 12 2015 PR Ipsen financial agenda 2016 FINAL ( pdf - 31 kB)
01 / 12 / 2015 - Paris (France)
Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial
Telotristat etiprate obtient des premiers résultats positifs dans une deuxième étude clinique de phase 3 ( pdf - 58 kB)
19 / 11 / 2015 - Paris (France)
Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
2015 11 19 PR Ipsen Interprotein peptides Cushing endocrinology FINAL ( pdf - 55 kB)
29 / 10 / 2015 - Paris (France)
Ipsen: sales in the 3rd quarter and first nine months of 2015
2015 10 29 PR Q3 & 9-month sales FINAL ( pdf - 125 kB)
28 / 10 / 2015 - Paris (France)
Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories
10-28-2015 PR Ipsen Telesta MCNA bladder FINAL ( pdf - 47 kB)
26 / 10 / 2015 - Paris (France)
Ipsen and EpiVax collaborate to produce next generation botulinum toxins
2015 10 26 Ipsen EpiVax next generation toxins ( pdf - 131 kB)
22 / 10 / 2015 - Paris (France)
Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy
2015 10 PR Dysport final results phase III PLL FINAL ( pdf - 99 kB)
19 / 10 / 2015 - Paris (France)
Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.
Cancer Patients Treated with Lexicon’s Telotristat Etiprate Report Improved Function and Well-Being ( pdf - 60 kB)
01 / 10 / 2015 - Paris (France)
Ipsen announces release of an additional batch of Increlex® in the U.S.
2015 10 01 PR Increlex resupply Corporate FINAL FINAL ( pdf - 74 kB)
01 / 10 / 2015 - Paris (France)
Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen
2015 10 01 PR Stéphane Bessette EVP RH (FINAL FINAL) ( pdf - 72 kB)
29 / 09 / 2015 - Paris (France)
Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.
Lexicon Telotristat Etiprate ( pdf - 60 kB)
31 / 08 / 2015 - Paris (France)
Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)
2015 08 31 Lancet Neurology Dysport ULS EN (FINAL) ( pdf - 79 kB)
03 / 08 / 2015 - Paris (France)
Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs
2015 08 03 telotristat etiprate ph3 results EN ( pdf - 298 kB)
31 / 07 / 2015 - Paris (France)
Ipsen: 2015 half-year results
2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2 ( pdf - 554 kB)
31 / 07 / 2015 - Paris (France)
Ipsen: 2015 half-year results and 2015 objectives
2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2 ( pdf - 554 kB)
Presentation H1 results FINAL ( pdf - 407 kB)
16 / 07 / 2015 - Paris (France)
Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States
PR AUL Approval FINAL ( pdf - 102 kB)
02 / 07 / 2015 - Paris (France)
Ipsen provides an update on 2020 strategy and outlook at Investor Day
PR Strategy 2020 EN - FINAL FINAL ( pdf - 35 kB)
Investor Day 02-07-2015 Presentation Media ( pdf - 966 kB)
03 / 06 / 2015 - Paris (France)
Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans
PR Rachat d'actions EN ( pdf - 168 kB)
02 / 06 / 2015 - Paris (France)
Ipsen confirms its eligibility for PEA-PME
PR PEA PME ( pdf - 92 kB)
29 / 05 / 2015 - Paris (France)
Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015
Communiqué Post-AG 2015 VA ( pdf - 223 kB)
19 / 05 / 2015 - Paris (France)
Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours
PR Ipsen Octreopharm EN - FINAL ( pdf - 80 kB)
29 / 04 / 2015 - Paris (France)
Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year
PR Q1 15 sales FINAL LAST 2 ( pdf - 81 kB)
16 / 04 / 2015 - Paris (France)
Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer
16042015 Ipsen Active Biotech discontinuatio 10Tasq10 FINAL ( pdf - 64 kB)
08 / 04 / 2015 - Paris (France)
Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors
08 04 2015 Ipsen Hannover Medical School PR FINAL ( pdf - 239 kB)
01 / 04 / 2015 - Paris (France)
Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
PR 01 04 2015 Cambridge Grand opening and Connecting with creativity EN ( pdf - 72 kB)
09 03 2015 IPSEN_Abstract_book-00 ( pdf - 1 MB)
01 / 04 / 2015 - Paris (France)
Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement
01 04 2015 PR Harvard Ipsen 2015 Research Alliance Agreement ( pdf - 57 kB)
31 / 03 / 2015 - Paris (France)
The Ipsen Group publishes its 2014 Registration document
PR DDR ( pdf - 112 kB)
04 / 03 / 2015 -
Precisions concerning the resupply of Increlex® in the U.S.
Precisions Increlex resupply 150304 ( pdf - 143 kB)
03 / 03 / 2015 - Paris (France)
Ipsen’s 2014 results and 2015 financial objectives
PR FY2014 results -FINAL ( pdf - 264 kB)
02 / 03 / 2015 - Paris (France)
Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer
PR appointment Dominique Laymand FINAL ( pdf - 222 kB)
02 / 03 / 2015 - Paris (France)
Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015
PR Increlex resupply 3rd batch US FINAL ( pdf - 113 kB)
24 / 02 / 2015 - Paris (France)
Ipsen enters into option agreement to acquire Canbex Therapeutics
24 02 2015 PR Canbex Ipsen Multiple sclerosis- Final FINAL ( pdf - 61 kB)
03 / 02 / 2015 - Paris (France)
Ipsen: sales in the fourth quarter and full year 2014
PR FY14 sales FINAL ( pdf - 198 kB)
26 / 01 / 2015 - Paris (France)
Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults
26012015 PR Dysport ALL & PLL ( pdf - 239 kB)
07 / 01 / 2015 - Paris (France)
Ipsen announces its corporate agenda for 2015
Ipsen - 2015 financial agenda ( pdf - 25 kB)
16 / 12 / 2014 - Paris (France)
François Garnier appointed Executive Vice President, General Counsel of Ipsen
12 2014 PR François Garnier_Nathalie Joannes General counsel EN ( pdf - 43 kB)
16 / 12 / 2014 - Paris (France)
Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
12 2014 corporate PR Approval Somatuline US FINAL ( pdf - 76 kB)
12 / 12 / 2014 - Paris (France)
Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen
12 12 2014 - PR IBCSG Decapeptyl Breast cancer EN FINAL ( pdf - 54 kB)
28 / 11 / 2014 - Paris (France)
Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients
28 11 2014 PR Dysport AUL sBLA FINAL ( pdf - 47 kB)
20 / 11 / 2014 - Paris (France)
Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA
RK rev 20 11 2014 PR Ipsen CNRS joint lab ARCHIPEX FINAL ( pdf - 343 kB)
18 / 11 / 2014 - Paris (France)
Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
18 11 2014 PR Ipsen Salk Insitute renewal agreement (FINAL) ( pdf - 298 kB)
06 / 11 / 2014 - Paris (France)
Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
06 11 2014 Press release Otonomy and Ipsen gacyclidine EN ( pdf - 82 kB)
29 / 10 / 2014 - Paris (France)
Ipsen: sales in the 3rd quarter and first nine months of 2014
29 10 2014 PR First 9 months 2014 sales ( pdf - 201 kB)
22 / 10 / 2014 - Paris (France)
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
22 10 2014 PR Ipsen Lexicon telotristat etiprate carcinoid syndrom EN ( pdf - 71 kB)
10 / 10 / 2014 - Paris (France)
Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
10 10 2014 PR appointment Aymeric Le Chatelier CFO (FINAL) ( pdf - 42 kB)
10 / 10 / 2014 - Paris (France)
Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients
10 10 2014 PR Decapeptyl subcutaneous administration prostate cancer FINAL ( pdf - 51 kB)
02 / 10 / 2014 - Paris (France)
Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities
2014 10 02 PR departure Susheel Surpal FINAL FINAL ( pdf - 38 kB)
27 / 09 / 2014 - Paris (France)
Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress
PR 27092014 TASQ phase II umbrella Final ( pdf - 93 kB)
01 / 09 / 2014 - Paris (France)
Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe
2014 09 01 PR acceptance filing Somatuline GEP NET US EU EN ( pdf - 116 kB)
29 / 08 / 2014 - Paris (France)
Ipsen: 2014 half-year results and 2014 objectives
PR H1 2014 FINAL ( pdf - 791 kB)
Télécharger la présentation ( pdf - 439 kB)
27 / 08 / 2014 - Basking Ridge (USA)
Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014
Télécharger ( pdf - 238 kB)
17 / 07 / 2014 - Paris (France)
New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Download ( pdf - 81 kB)
11 / 07 / 2014 - Paris (France)
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
PR Ipsen - Galderma FINAL ( pdf - 300 kB)